Transaction · 0001209191-24-000364

Piscitelli Dominic

Piscitelli Dominic, CFO, reported a transaction classified as grant at Oric Pharmaceuticals, Inc. involving 30000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 30000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACFO
ORICOric Pharmaceuticals, Inc.
Filing timeJan 03
Trade dateJan 02, 2024
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

ORIC price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ORIC since 2024-01-03Filed 975 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001209191-24-000364
Restricted Stock Unit
Transaction date
Jan 02, 2024
Filed Jan 03, 2024, 04:18 PM · 1d delay
Shares
30.0k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
30.0k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

  2. F2

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

  3. F3

    1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

Original filing · 0001209191-24-000364
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ORIC